Photo

Photo detail

Stories this photo appears in:

Ligand Pharmaceuticals Acquires a Portfolio From Swiss Firm for $4 Million

Ligand Pharmaceuticals Inc. has spent $4 million to acquire a portfolio of more than 15 biologic development programs from Swiss biotech firm Selexis SA, which could provide future milestone and royalty payments.

Tease photo

Ligand Reports Q4 Net Income of $7.1M

Ligand Pharmaceuticals Inc., a San Diego-based biotechnology firm, posted quarterly earnings results.

Tease photo

Ligand Earns Milestone Payment for Role in Assisting a Merck Drug Approval

Ligand Pharmaceuticals Inc. announced that Merck & Co. Inc., known as MSD outside the United States and Canada, has received approval for its drug candidate,Noxafil, which was created using technology enabled by Ligand’s Captisol.

Tease photo

Ligand Pharmaceuticals Earns Milestone Payment From Merck

Ligand Pharmaceuticals Inc. announced that Merck & Co. Inc., known as MSD outside the United States and Canada, has received approval for its drug candidate,Noxafil, which was created using technology enabled by Ligand’s Captisol.

Tease photo

Ligand Signs Licensing Agreement With Georgia Company

Ligand Pharmaceuticals Inc. announced the signing of a commercial license agreement with Atlanta, Georgia-based Avion Pharmaceuticals LLC for the development and commercialization of four Captisol-enabled programs

Tease photo

Ligand to Offer $225 Million in Senior Convertible Notes, Authorizes $200M Share Buyback

San Diego-based Ligand Pharmaceuticals Inc. announced that it intends to offer $225 million of convertible senior notes due 2019 and has authorized a $200 million share repurchase program over the next 12 months.

Tease photo

Ligand Inks Licensing Agreement With TG Therapeutics

Ligand Pharmaceuticals Inc. has signed an exclusive global license agreement with TG Therapeutics Inc. for the development and commercialization of Ligand’s Interleukin-1 Receptor Associated Kinase-4 — or IRAK-4 — inhibitors, Ligand announced.

Tease photo

Ligand Pharmaceuticals Does Licensing Deal and Investment With San Diego Startup

San Diego-based Ligand Pharmaceuticals Inc. has licensed five of its programs to Viking Therapeutics Inc.; Ligand is also investing $2.5 million in Viking, a San Diego startup.

Tease photo

Ligand's Revenue Increases 37% for Q1

Ligand Pharmaceuticals Inc. grew revenue for the first quarter ended March 31, 2014 by 37 percent to $16 million, and its royalty revenues increased 35 percent to $7.9 million.

Tease photo